Depatuxizumab mafodotin for recurrent EGFR-amplified glioblastoma multiforme
NIHR HSRIC
Record ID 32016001027
English
Authors' recommendations:
Depatuxizumab mafodotin is a new drug to treat a type of brain cancer called recurrent EGFR-amplified glioblastoma multiforme. Glioblastoma is the most common type of brain cancer and develops from cells that support the nerve tissue. Depatuxizumab mafodotin may offer a new treatment option for patients with recurrent EGFR-amplified glioblastoma multiforme whose first treatment has failed and may improve survival when other drugs have failed to work.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/depatuxizumab-mafodotin-for-recurrent-egfr-amplified-glioblastoma-multiforme/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Brain Neoplasms
- Glioblastoma
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.